and Xiao-Hong Sun1,2,3*
Immunobiology and Cancer Program, Oklahoma Medical Research Foundation,1 Department of Microbiology and Immunology,2 Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma3
Received 6 May 2004/ Returned for modification 17 June 2004/ Accepted 19 July 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The molecular mechanism underlying Notch-induced E2A ubiquitination is not known. To obtain a better understanding of the mechanism, a more comprehensive knowledge about the machinery responsible for E2A ubiquitination is necessary. Our laboratory has previously shown that the SCFSkp2 E3 ubiquitin ligase complex, including Cul1, Skp1, Skp2 and Roc1, is involved in E2A ubiquitination (17, 30). Interaction between Skp2 and E2A proteins depends on E2A phosphorylation. To search for possible additional components involved in E2A degradation, we used a fragment of E2A known to be crucial for its degradation as bait to conduct a Saccharomyces cerevisiae two-hybrid screen. We identified CHIP as an interacting partner of E47 not only in yeast but also in mammalian cells.
CHIP is a cochaperone protein identified through its interaction with Hsc70 (5). In addition to its well-characterized tetratricopeptide repeats (TPR) that mediate interaction with chaperones (15, 40), it also has a U-box, representing a subclass of ubiquitin ligases (13, 23). Diverse functions have been ascribed to CHIP. CHIP itself has been shown to possess E3 ubiquitin ligase activity by using luciferase, ErbB2, Hsc70, and CHIP as substrates (7, 18, 28, 45). However, CHIP has also been shown to facilitate the ubiquitination of Pael receptor and cystic fibrosis transmembrane-conductance regulator by other E3 ligases (16, 26). In addition, CHIP is postulated to be a cochaperone that facilitates the degradation of misfolded proteins (1, 8, 10, 44). Moreover, CHIP also performs functions unrelated to protein ubiquitination and degradation, such as inducing the trimerization of HSF transcription factor and partitioning soluble endothelial nitric oxide synthase into an insoluble and inactive cellular compartment (9, 19). Here we provide evidence suggesting that CHIP acts as a carrier of the ubiquitination substrate, E47, thus promoting its association with the F box protein Skp2, through the formation of a preubiquitination complex (PUC). CHIP also binds to Cul1, ultimately facilitating the assembly of the entire SCFSkp2-E3 ligase complex and the ubiquitination of E47. This function of CHIP is essential for Notch-induced E2A degradation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell lines and transfection. NIH 3T3 and 293T cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The BaF3 cell line was grown in modified RPMI 1640 supplemented with 10% fetal bovine serum, 50 µM ß-mercaptoethanol, and 20% WEHI-3-conditioned medium as a source of interleukin-3. Jagged-1-expressing and control NIH 3T3 cell lines were generous gifts from T. Kadesch, University of Pennsylvania. Transient transfection with desired constructs was performed using the calcium phosphate precipitation method.
Plasmids and retroviral constructs. Full-length CHIP cDNA with a 3' hemagglutinin (HA) tag was cloned by PCR amplification using total mouse cDNA as templates and the following primers: 5' primer, ATTGGTACCATGAAGGGCAAGGAGGAAAAGGAG; 3' primer, TTCAGGCGTAGTCTGGGACGTCCTAAGGGTAATAGTCCTCTACCCAGCCGTTCTCAG. The PCR product was first cloned into the pGEM-T easy vector (Promega, Madison, Wis.). The insert was then excised out with Asp718 and EcoR1 and cloned into the same sites of pcDNA3 (Invitrogen, Carlsbad, Calif.). HPC4-tagged CHIP-pcDNA3 was generated by inserting oligonucleotides containing sequences encoding the HPC4 tag (38) into the Asp718 site at the 5' end of CHIP in pcDNA3. The CHIP K31A point mutant was generated by replacing the wild-type SacI-Bpu11021 fragment within the coding sequence with a mutant fragment generated by PCR amplification with the following oligonucleotides: 5' primer, AGAGCTCGCGGAGCAGGGAAAC (mutated codon is underlined); 3' primer, TGAATTCAATCATCTTCATGACCCTCGTGG. The CHIP H261A/P270A point mutant construct (13) was obtained from S. Hatakeyama, University of Kyushu, Fukuoka, Japan, and modified by swapping the 5' portion of the wild-type CHIP with the HPC4 tag. To produce TPR and U-box domain-containing constructs, we performed PCR using CHIP-pcDNA3 as a template with the following oligonucleotides: for TPR, TGGATCCATGAAGGGCAAGGAGGAAAAGG and TGAATTCAATCATCTTCATGACCCTCGTGG; for U-box, TGGATCCAAGAAGCGCTGGAACAGTATCGAGG and TGAATTCACTAGTGATTTCAGGCGTAG. The PCR products were cloned into the BamHI and EcoRI sites of the pcDNA3 vector carrying the HPC4 tag at the Asp718 site. To generate the RNA interference construct targeting CHIP, double-stranded oligonucleotides containing a hairpin structure were cloned into the XhoI and HindIII sites of the pBS/U6 vector (41). The top-strand sequence of the oligonucleotides for small interfering RNA (siRNA) against CHIP (CHIPi) was TCGAGGAAGCGAGATATCCCTGACGAGTACTGGTCAGGGATATCTCGCTTCCTTTT, and that for siRNA against green fluorescent protein (GFPi) was as described elsewhere (30). Retroviral constructs for CHIPi and GFPi were generated by inserting the BamHI-EcoRI fragments containing the entire U6 transcription units from the above pBS/U6 constructs into the BglII and EcoRI sites of the MiGR1 vector (36). Retrovirus production was carried out as described previously (34).
E47 point and deletion mutants were made by two-step PCR-assisted mutagenesis using the parental plasmid E47-pcDNA3 as a template (33). T7-tagged Skp2 construct was a gift from H. Zhang, Yale University School of Medicine. The Skp2 construct used for in vitro translation was generated by PCR amplification of the coding sequence of Skp2 using the T7-tagged Skp2 construct as a template. The PCR product was cloned into the Asp718 and EcoRI sites of pcDNA3. The constructs, Cul1-pcDNA3 and HA-Skp1-pHR, were kindly provided by W. Harper, Harvard Medical School.
Immunoblotting and immunoprecipitation. Cells were collected and lysed in NP-40 lysis buffer containing 15 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.1 mM EDTA, 10% glycerol, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, 2 µg of aprotinin/ml, 4 µg of leupeptin/ml, 2 µg of pepstain/ml, and 5 µM MG132. Supernatants were obtained after centrifugation at 20,000 x g in a microcentrifuge for 15 min at 4°C. Protein concentrations were determined by BCA protein assay kit (Pierce, Rockford, Ill.). For immunoblotting, cells were collected 36 h after transfection. For in vivo ubiquitination assays, cells were treated with 25 µM MG132 for 5 h prior to harvest. The immunoreactive proteins were detected using enhanced chemiluminescence reagents (Amersham, Piscataway, N.J.) and a LumiImager (FUJIFILM Medical Systems USA Inc., Stamford, Conn.). Loading controls were carried out by probing for ß-actin. Antibodies against E47, Hsc70, HA tag, and ß-actin were from Santa Cruz Biotechnology (Santa Cruz, Calif.), while those against Skp1 and Cul1 were from NeoMarkers (Fremont, Calif.). Anti-Skp2 was purchased from Zymed (San Francisco, Calif.). The antiserum against CHIP was generated by immunizing rabbits with full-length recombinant CHIP (carried out by Pocono Rabbit Farm & Laboratory Inc., Canadensis, Pa.). For immunoprecipitation assays, cell lysates were precleared with 60 µl of protein A or protein A/G-Sepharose (50% slurry equilibrated in phosphate-buffered saline) for 2 h at 4°C and then incubated with 5 µg of specific antibodies for 4 to 5 h at 4°C. Protein A or protein A/G-Sepharose was added and incubated for an additional 1 h at 4°C to capture primary immune complexes. The beads were washed three times in NP-40 lysis buffer and heated at 100°C in sodium dodecyl sulfate (SDS) sample buffer before loading on 10 or 12% polyacrylamide gels. For immunoprecipitation with the anti-HPC4 antibody (a generous gift from C. Esmon, Oklahoma Medical Research Foundation), which binds to the HPC4 tag in a calcium-dependent manner (38), 1 mM CaCl2 was included in all buffers used. The immunoprecipitates were eluted with 10 mM EDTA by shaking for 30 min at room temperature. The SDS loading buffer was then added to the supernatants, and the samples were boiled before electrophoresis.
In vitro translation and binding assays. 35S-labeled Skp1, Skp2, Cul1, and CHIP were produced by programming the TNT-coupled reticulocyte lysate in vitro translation system (Promega) with 1 µg of each expression plasmid DNA, according to the manufacturer's instructions. A 50-µl aliquot of in vitro-translated reaction mixtures diluted with 300 µl of NP-40 lysis buffer was used for immunoprecipitation with the antibody against the HPC4 tag on CHIP. The resulting immunoprecipitates were electrophoresed on SDS-10% polyacrylamide gels and analyzed by autoradiography using a PhosphorImager.
| RESULTS |
|---|
|
|
|---|
|
Furthermore, because CHIP was previously reported to be localized to the cytoplasm and E2A proteins are in the nucleus (5, 26), an issue arises as to whether the two proteins have any opportunity to interact with each other. To clarify this issue, we prepared cytoplasmic and nuclear fractions from BaF3 cells and examined the relative levels of these proteins (Fig. 1C). While the majority of E2A proteins were present in the nucleus and CHIP was in the cytoplasm, a small fraction of CHIP was found in the nucleus. This was not due to contamination of the nuclear fraction with the cytoplasmic fraction, because actin was detected only in the cytoplasmic fraction when the same membrane was reprobed for actin. However, the small amount of E2A proteins in the cytoplasmic fraction might be due to contamination from broken nuclei or proteins transiting the cytoplasm as they are newly synthesized or degraded. To examine the interaction between E2A and CHIP in cytoplasmic and nuclear fractions, we carried out coimmunoprecipitation experiments (Fig. 1C). In the cytoplasmic fraction, very low levels of E2A proteins were detected in the anti-CHIP precipitates despite a large amount of CHIP brought down by the antiserum against CHIP. This is because E2A proteins are rarely present in the cytoplasm. In contrast, the anti-CHIP immunoprecipitates from the nuclear fraction brought down a substantial amount of E2A proteins. A preimmune serum was also used in parallel as a negative control. These results suggest that a small portion of CHIP is present in the nucleus and capable of interacting with E2A proteins in vivo.
CHIP is important for E47 degradation. Next, we examined the effect of CHIP on E47 degradation. E47 was cotransfected with increasing amounts of the CHIP expression construct into NIH 3T3 cells. The amount of E47 present in transfected cells was measured by immunoblotting with anti-E47 antibodies. With an increasing amount of CHIP expressed, the amount of wild-type E47 decreased, but that of the E47 Mm mutant remained unchanged (Fig. 2A). This result suggested that CHIP facilitated the degradation of E47 in a phosphorylation-dependent manner. It should be noted that induction of E47 degradation by CHIP is not apparent in 293T cells. This is probably because E47 is expressed at much higher levels in these cells, thus overwhelming endogenous degradation machineries. We also found that, compared to NIH 3T3 cells, 293T cells have much lower MAP kinase activities, which are required for E47 phosphorylation prior to its degradation. Therefore, the 293T cell line is ideal for examining protein interaction but not for E47 degradation.
|
Mutational analysis of the CHIP-binding domain in E47. To map the CHIP-interacting domain in E47, we first focused on the region originally used for screening the yeast two-hybrid library and identifying CHIP as an interacting protein. This region contains two domains highly conserved in all E proteins, called EHD2 and EHD3 (Fig. 3A). EHD3 carries the MAP kinase sites shown to be important for Skp2 binding and E47 ubiquitination. CHIP was cotransfected into 293T cells with various E47 mutants, and whole-cell lysates were prepared 36 h after transfection. Coimmunoprecipitation experiments were carried out with the monoclonal antibody against the HPC4 tag on CHIP, and the precipitates were analyzed by immunoblotting with anti-E47 antibodies (Fig. 3B). The amount of CHIP brought down in each reaction was determined by anti-HPC4 immunoblotting, while the expression level of each E47 construct was measured by immunoblotting the whole-cell extract with anti-E47 antibodies. Deletion of EHD2 and -3 individually or together dramatically decreased the interaction of E47 with CHIP in coimmunoprecipitation assays, suggesting that both domains are involved in the interaction (Fig. 3B). The extremely low level of interaction remaining in these constructs might result from interaction with the junction sequences on either side of EHD2 plus -3 or from a nonspecific interaction of the mutants with the anti-HPC4 antibody. Furthermore, point mutations in EHD2 and EHD3 were also examined in the same manner (Fig. 3B). Surprisingly, mut1 and mut5, located at the N terminus of EHD2 and the C terminus of EHD3, respectively, lost most of their ability to bind to CHIP. In contrast, clusters of mutations near the junction of EHD2 and -3 in mut2, mut3, and mut4 (also known as Mm) constructs had little or no effect on CHIP interaction (Fig. 3B). Taken together, it appears that EHD2 and -3 together form a CHIP binding domain and CHIP binds to both ends of the domain, leaving the internal region available for Skp2 interaction.
|
EHD23 mutant lacking the entire CHIP interacting domain was resistant to CHIP-induced degradation. Similarly, the mut1 point mutant was neither bound by CHIP nor induced to degrade by CHIP. In contrast, the level of mut2 was sensitive to CHIP, because mut2 was capable of interaction with CHIP. Therefore, these results further confirm the involvement of CHIP in E47 degradation. Mutational analysis of the E47 binding domain in CHIP and the functional consequences of the mutations. CHIP contains two well-characterized domains: the TPR domain responsible for chaperone binding, and the U-box domain important for its E3 ubiquitin ligase activity (8). Coimmunoprecipitation assays were performed by incubating antibodies against E47 with whole-cell lysates prepared from 293T cells transfected with E47 and wild-type or mutant CHIP. The precipitates were analyzed by immunoblotting with the anti-HPC4 antibody to detect CHIP (Fig. 4A). The TPR domain, located 28 amino acids downstream from the N terminus, was necessary and sufficient for E47 binding, but the K31A point mutation within the TPR domain, known to disrupt interaction with chaperones (45), did not affect E47 binding. This suggests that CHIP associates with E47 independently of chaperones. However, the U-box domain did not associate with E47 (Fig. 4A). Intriguingly, the H261A and P270A mutations within the U-box, thought to inhibit the ubiquitin ligase activity (13), also impaired the interaction between E47 and CHIP. This is in contrast to the finding with the TPR construct, that complete deletion of the U-box domain in the TPR construct had minimal effect on E47 interaction. We hypothesize that the integrity of the U-box domain or the ubiquitin ligase activity is necessary for maintaining a proper conformation to allow the TPR domain to bind to E47. A charged region lies between the TPR domain and the U-box which has recently been shown to mediate dimerization of CHIP (31). Since this domain is present in both the TRP and U-box constructs, it is unlikely involved in binding to E47.
|
Since we had previously shown that E47 degradation is ubiquitin mediated, we examined the effect of CHIP on E47 ubiquitination (Fig. 4C). E47 was cotransfected into 293T cells with an HA-tagged ubiquitin construct along with wild-type or mutant CHIP constructs. Immunoprecipitation was carried out with antibodies against E47, and the precipitates were analyzed by immunoblotting with anti-HA and anti-E47 antibodies. Coexpression of wild-type CHIP with E47 dramatically enhanced the ubiquitination of E47, suggesting that CHIP is involved in the process of E47 ubiquitination. Consistent with the effects of CHIP mutants on E47 degradation, the TPR domain stimulated E47 ubiquitination, while the U-box domain as well as the K31A and H261A-P270A mutants did not alter the level of E47 ubiquitination. Therefore, we conclude that the TPR domain of CHIP is responsible for facilitating E47 degradation by enhancing its ubiquitination. Furthermore, the inability of the K31A mutant to promote E47 degradation indicates that although the ability of CHIP to bind to chaperones is not necessary for binding to E47, it is required for promoting E47 ubiquitination and degradation.
CHIP binds to SCFskp2 through interaction with Cul1. To understand the mechanism by which CHIP enhances E47 ubiquitination, we examined the association between CHIP and the SCFskp2 complex, which we have previously shown to be involved in E47 ubiquitination (30). CHIP or its deletion mutants were transfected with or without E47 into 293T cells. Immunoprecipitation was carried out using the antibody against the HPC4 tag on CHIP or a control antibody. The immunoprecipitates were analyzed by blotting with antibodies against components of the SCFskp2 complex (Fig. 5A). CHIP or the mutant containing the TPR domain (lanes 2 to 4) coimmunoprecipitated with components of the endogenous SCFSkp2 complexes, including Cul1, Skp2, Skp1, and Roc1 (12). However, expression of the mutant containing the U-box domain did not lead to coprecipitation with SCFSkp2, as shown by the comparable amounts of each component brought down with the anti-HPC4 and control antibodies (lanes 1 and 5). These results suggested that the TPR domain mediates the interaction between CHIP and SCFSkp2, which is consistent with its role in stimulating E47 ubiquitination and degradation (Fig. 4). The interaction between CHIP and SCFskp2 was independent of E47, since the amounts of SCFskp2 components bound to CHIP were similar in cells transfected with and without E47 (Fig. 5A).
|
|
Significantly, expression of Skp2 drastically increased the amount of CHIP coprecipitated without increasing the amounts of Cul1 and Skp1, suggesting that Skp2 and CHIP form an additional non-SCF complex, which we named the PUC (Fig. 6A, compare lanes 3 and 4 to lanes 5 and 6). In fact, amounts of Cul1 and Skp1 in the anti-Skp2 precipitates in lane 5 were lower than that in lane 3. This may be explained by the fact that overexpressed Skp2 was able to increase the amount of PUC, but the amount of SCF complex was limited by the quantity of Cul1 available in the cells. Therefore, PUC or free Skp2 outcompeted the SCF complex for anti-Skp2 antibodies during immunoprecipitation. When Cul1 was also overexpressed (lane 6), the amounts of Cul1 and Skp1 coprecipitated were increased. Moreover, the amount of endogenous Hsc70 coprecipitated was significantly elevated by overexpression of Skp2 but not Cul1 (compare lanes 4 and 5), thus raising the possibility that PUC also contains Hsc70.
Data shown in Fig. 6A led us to postulate that CHIP and its interacting partner, Hsc70, provide a scaffold for the formation of PUC that promotes the interaction between the F-box protein of the SCF complex, Skp2, and its substrate, E47. Therefore, CHIP binds to E47 on one hand and Hsc70 on the other. Similarly, Hsc70 interacts with both CHIP and Skp2. Together, this tetrameric complex brings E47 and Skp2 together and allows Skp2 to recognize and bind with high affinity to phosphorylated E47. To test this hypothesis, E47 and Skp2 were cotransfected with or without wild-type CHIP or with CHIP mutants defective in binding to either Hsc70 or E47. Immunoprecipitation was carried out with anti-Skp2 or control antibodies. Amounts of coprecipitated E47, Hsc70, and CHIP were assayed by immunoblotting (Fig. 6B). In the absence of CHIP, anti-Skp2 antibodies brought down a small amount of E47, likely via interaction with endogenous CHIP (lane 2). However, coexpression with CHIP dramatically increased the amount of E47 coprecipitated, suggesting that CHIP indeed facilitated the interaction between E47 and Skp2 (lane 3). In contrast, the K31A and H261A-P270A mutants of CHIP failed to facilitate coimmunoprecipitation of E47 and Skp2 (lanes 4 and 5). Since the K31A mutant is defective in binding to Hsc70 (45) and the H261A-P270A mutant does not bind to E47 (Fig. 4A), these results thus suggest that the ability of CHIP to promote E47 and Skp2 interaction depends on its activities in interacting with both E47 and Hsc70. Hsc70, however, was found to bind to Skp2 in the presence or absence of wild type and mutant CHIP, indicating its direct interaction with Skp2 (Fig. 6B, lanes 2 to 5). Moreover, CHIP could associate with Skp2 only if it was able to interact with Hsc70 (compare lane 3 to lane 4), which is consistent with the finding that CHIP did not bind to Skp2 directly (Fig. 5C). The H261A-P270A mutant was pulled down readily by anti-Skp2 antibodies but failed to assist in recruiting of E47 due to its poor affinity to E47 (lane 5). Taken together, these results suggest that components of PUC connect linearly in the order of E47-CHIP-Hsc70-Skp2 (Fig. 7).
|
| DISCUSSION |
|---|
|
|
|---|
Ubiquitination of proteins destined for degradation is mostly accomplished through cooperation of three enzymes with ubiquitin-activating, -conjugating, and -ligating activities, namely E1, E2, and E3 (35). It is believed that in mammalian cells a single E1 enzyme exists to serve the activating function for several E2 enzymes. The large number and diversity of E3 ligase complexes are thought to be responsible for substrate specificity, for example, by specific interaction between the F-box-containing component of the SCF complex and the substrate (12, 20). Even so, it would not seem economical to assign thousands of E3 ligase complexes to the same number of proteins to be ubiquitinated so that each substrate would have its own E3 ligase. Additional layers of complexity could be provided by forming PUCs, which may augment substrate specificity or affinity between substrates and E3 ligases. We propose the presence of one such complex for the E47 substrate which consists of E47, CHIP, Hsc70, and Skp2 (Fig. 7).
The purpose of forming PUC for E12/E47 is probably to facilitate their interaction with the substrate-recognizing subunit of the SCF complex, Skp2. Because of the relatively low abundance of E12/E47 and Skp2, the opportunity for them to interact with each other would be significantly increased if they independently bound to the scaffold provided by CHIP and Hsc70. CHIP mutants that fail to mediate the formation of PUC, such as the K31A and H261A-P270A mutants, are incapable of stimulating E47 degradation (Fig. 4). However, PUC would be rather indiscriminate, because CHIP is able to bind to E47 with or without its phosphorylation by MAP kinases, which is known to be required for high-affinity binding of E47 to Skp2 and ubiquitination of E47. Therefore, phosphorylation of E47 might induce a conformational change in PUC to allow a better fit between E47 and Skp2, preparing them to enter the E3 ligase complex. Furthermore, the affinity of CHIP to Cul1 may also enable CHIP to introduce the E47-containing PUC to the SCF complex and promote the ubiquitination of E47. Cul1 appears to play an important role in assembling the SCF complex, since overexpression of Cul1 not only increased the amount of Cul1 coprecipitated with CHIP but also those of other components of the SCF complex. Taken together, CHIP, through its multiple interfaces with Hsc70, E47, and Cul1, plays a crucial role in the ubiquitination process of the E47 transcription factor. We propose that CHIP mediates the formation of PUC and SCFskp2 based on results from overexpression and coimmunoprecipitation studies. The confirmation for the existence of these complexes awaits elaborate biochemical fractionation.
A similar cast of characters as those described here has also been shown to be involved in the ubiquitination of the Pael receptor by Parkin (16). Parkin is a ring-finger-containing subunit of the E3 ubiquitin ligase, whose mutation is responsible for juvenile Parkinson's disease (22). In this case, CHIP and Hsp70/Hsc70 interact with Parkin and its substrate, the membrane-bound Pael-R. Similar to its role in E47 ubiquitination, CHIP enhances the ubiquitin ligase function of Parkin. However, there are several important differences. First, Parkin interacts with either CHIP or Hsp70/Hsc70 mutually exclusively, while Skp2 only binds to Hsc70 but not CHIP. Second, CHIP associates with E47 but not Pael-R. Finally, the U-box domain is necessary for Parkin interaction, while the TPR domain of CHIP is required for binding to E47. Consequently, these differences lead to different mechanisms of action proposed for CHIP: CHIP displaces Hsp70/Hsc70 to take misfolded Pael-R from the endoplasmic reticulum (ER) to ubiquitination and degradation. A similar mechanism has also been ascribed to the degradation of the immature cystic fibrosis transmembrane conductance regulator (26). Therefore, it has been established that CHIP plays an important role in quality control for proteins synthesized and matured through the ER (8). In contrast, CHIP, together with Hsc70, facilitates the ubiquitination of the nuclear protein E47 by forming a PUC before joining the SCF-E3 ligase complex. Production of E47 does not involve ER, and E47 does not directly bind to Hsc70 or Hsp90 (data not shown). It is likely that the E47-containing PUC forms in the nucleus (Fig. 1C). E47 is the first nuclear protein shown to associate with CHIP, even though other transcriptional regulators, such as Smads, also bind to CHIP (24). However, these proteins stay in the cytoplasm and only translocate to the nucleus upon activation.
Despite the ubiquitin ligase activity associated with its U-box domain, CHIP did not act as an E3 ligase for E47 because the U-box domain is dispensable for its function in stimulating E47 ubiquitination and degradation. This is an unusual feature of CHIP, which appears to act more as an adaptor than as an enzyme to enhance the efficiency of E2A ubiquitination. Intriguingly, although deletion of the U-box domain did not alter its effect on E47, point mutations in the U-box domain which abolished the ubiquitin ligase activity disrupted the interaction between CHIP and E47. This raises an interesting question as to whether the ubiquitin ligase activity of CHIP, through autoubiquitination, augments its own conformation and consequently controls its ability to interact with different proteins. The answer to this question awaits further investigation.
| ACKNOWLEDGMENTS |
|---|
The work was supported by grants from the National Institutes of Health to X.-H.S. (AI33597, CA77553, AI056129, and RR15577 [COBRE award]). Z.H. was funded by training grant 1T32-AI07633-01A1 from the National Institute of Allergy and Infectious Diseases.
| FOOTNOTES |
|---|
Present address: Howard Hughes Medical Institute, Division of Infectious Diseases, University of California San Francisco, San Francisco, CA 94143. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Allman, D., J. A. Punt, D. J. Izon, J. C. Aster, and W. S. Pear. 2002. An invitation to T and more: notch signaling in lymphopoiesis. Cell 109(Suppl.):S1-S11.
3. Bain, G., I. Engel, E. C. Robanus Maandag, H. P. te Riele, J. R. Voland, L. L. Sharp, J. Chun, B. Huey, D. Pinkel, and C. Murre. 1997. E2A deficiency leads to abnormalities in
ß T-cell development and to rapid development of T-cell lymphomas. Mol. Cell. Biol. 17:4782-4791.[Abstract]
4. Bain, G., E. C. Robanus Maandag, D. J. Izon, D. Amsen, A. M. Kruisbeek, B. Weintraub, I. Krop, M. S. Schlissel, A. J. Feeney, M. van Roon, M. van der Valk, H. P. J. te Riele, A. Berns, and C. Murre. 1994. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 79:885-892.[CrossRef][Medline]
5. Ballinger, C. A., P. Connell, Y. Wu, Z. Hu, L. J. Thompson, L. Y. Yin, and C. Patterson. 1999. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19:4535-4545.
6. Barndt, R. J., M. Dai, and Y. Zhuang. 2000. Functions of E2A-HEB heterodimers in T-cell development revealed by a dominant negative mutation of HEB. Mol. Cell. Biol. 20:6677-6685.
7. Connell, P., C. A. Ballinger, J. Jiang, Y. Wu, L. J. Thompson, J. Hohfeld, and C. Patterson. 2001. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3:93-96.[CrossRef][Medline]
8. Cyr, D. M., J. Hohfeld, and C. Patterson. 2002. Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem. Sci. 27:368-375.[CrossRef][Medline]
9. Dai, Q., C. Zhang, Y. Wu, H. McDonough, R. A. Whaley, V. Godfrey, H. H. Li, N. Madamanchi, W. Xu, L. Neckers, D. Cyr, and C. Patterson. 2003. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 22:5446-5458.[CrossRef][Medline]
10. Demand, J., S. Alberti, C. Patterson, and J. Hohfeld. 2001. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr. Biol. 11:1569-1577.[CrossRef][Medline]
11. Gyuris, J., E. Golemis, H. Chertkov, and R. Brent. 1993. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75:791-803.[CrossRef][Medline]
12. Harper, J. W. 2001. Protein destruction: adapting roles for Cks proteins. Curr. Biol. 11:R431-R435.[CrossRef][Medline]
13. Hatakeyama, S., M. Yada, M. Matsumoto, N. Ishida, and K. I. Nakayama. 2001. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276:33111-33120.
14. Heemskerk, M. H., B. Blom, K. Oda, A. P. Stegmann, A. Q. Bakker, K. Weijer, P. C. Res, and H. Spits. 1997. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J. Exp. Med. 186:1597-1602.
15. Hirano, T., N. Kinoshita, K. Morikawa, and M. Yanagida. 1990. Snap helix with knob and hole: essential repeats in S. pombe nuclear protein nuc2+. Cell 60:319-328.[CrossRef][Medline]
16. Imai, Y., M. Soda, S. Hatakeyama, T. Akagi, T. Hashikawa, K. I. Nakayama, and R. Takahashi. 2002. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell 10:55-67.[CrossRef][Medline]
17. Jackson, P. K., and A. G. Eldridge. 2002. The SCF ubiquitin ligase: an extended look. Mol. Cell 9:923-925.[CrossRef][Medline]
18. Jiang, J., C. A. Ballinger, Y. Wu, Q. Dai, D. M. Cyr, J. Hohfeld, and C. Patterson. 2001. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 276:42938-42944.
19. Jiang, J., D. Cyr, R. W. Babbitt, W. C. Sessa, and C. Patterson. 2003. Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the co-chaperone/ubiquitin ligase CHIP. J. Biol. Chem. 278:49332-49341.
20. Karin, M., and Y. Ben Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-
B activity. Annu. Rev. Immunol. 18:621-663.[CrossRef][Medline]
21. Kim, D., X. C. Peng, and X. H. Sun. 1999. Massive apoptosis of thymocytes in T-cell-deficient Id1 transgenic mice. Mol. Cell. Biol. 19:8240-8253.
22. Kitada, T., S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, M. Yokochi, Y. Mizuno, and N. Shimizu. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.[CrossRef][Medline]
23. Koegl, M., T. Hoppe, S. Schlenker, H. D. Ulrich, T. U. Mayer, and S. Jentsch. 1999. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635-644.[CrossRef][Medline]
24. Li, L., H. Xin, X. Xu, M. Huang, X. Zhang, Y. Chen, S. Zhang, X. Y. Fu, and Z. Chang. 2004. CHIP mediates degradation of Smad proteins and potentially regulates Smad-induced transcription. Mol. Cell. Biol. 24:856-864.
25. Massari, M. E., and C. Murre. 2000. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol. Cell. Biol. 20:429-440.
26. Meacham, G. C., C. Patterson, W. Zhang, J. M. Younger, and D. M. Cyr. 2001. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. 3:100-105.[CrossRef][Medline]
27. Morrow, M. A., E. W. Mayer, C. A. Perez, M. Adlam, and G. Siu. 1999. Overexpression of the helix-loop-helix protein Id2 blocks T cell development at multiple stages. Mol. Immunol. 36:491-503.[CrossRef][Medline]
28. Murata, S., Y. Minami, M. Minami, T. Chiba, and K. Tanaka. 2001. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep. 2:1133-1138.[CrossRef][Medline]
29. Murre, C., P. S. McCaw, and D. Baltimore. 1989. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD and myc proteins. Cell 56:777-783.[CrossRef][Medline]
30. Nie, L., M. Xu, A. Vladimirova, and X. H. Sun. 2003. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J. 22:5780-5792.[CrossRef][Medline]
31. Nikolay, R., T. Wiederkehr, W. Rist, G. Kramer, M. P. Mayer, and B. Bukau. 2004. Dimerization of the human E3 ligase CHIP via a coiled-coil domain is essential for its activity. J. Biol. Chem. 279:2673-2678.
32. Ordentlich, P., A. Lin, C. P. Shen, C. Blaumueller, K. Matsuno, S. Artavanis-Tsakonas, and T. Kadesch. 1998. Notch inhibition of E47 supports the existence of a novel signaling pathway. Mol. Cell. Biol. 18:2230-2239.
33. Park, S. T., and X. H. Sun. 1998. The Tal1 oncoprotein inhibits E47-mediated transcription. Mechanism of inhibition. J. Biol. Chem. 273:7030-7037.
34. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
35. Pickart, C. M. 2001. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:503-533.[CrossRef][Medline]
36. Pui, J. C., D. Allman, L. Xu, S. DeRocco, F. G. Karnell, S. Bakkour, J. Y. Lee, T. Kadesch, R. R. Hardy, J. C. Aster, and W. S. Pear. 1999. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11:299-308.[CrossRef][Medline]
37. Radtke, F., A. Wilson, and H. R. MacDonald. 2004. Notch signaling in T- and B-cell development. Curr. Opin. Immunol. 16:174-179.[CrossRef][Medline]
38. Rezaie, A. R., M. M. Fiore, P. F. Neuenschwander, C. T. Esmon, and J. H. Morrissey. 1992. Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody. Protein Expr. Purif. 3:453-460.[CrossRef][Medline]
39. Schulman, B. A., A. C. Carrano, P. D. Jeffrey, Z. Bowen, E. R. Kinnucan, M. S. Finnin, S. J. Elledge, J. W. Harper, M. Pagano, and N. P. Pavletich. 2000. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 408:381-386.[CrossRef][Medline]
40. Sikorski, R. S., M. S. Boguski, M. Goebl, and P. Hieter. 1990. A repeating amino acid motif in CDC23 defines a family of proteins and a new relationship among genes required for mitosis and RNA synthesis. Cell 60:307-317.[CrossRef][Medline]
41. Sui, G., C. Soohoo, E. B. Affar, F. Gay, Y. Shi, W. C. Forrester, and Y. Shi. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99:5515-5520.
42. Sun, X.-H. 1994. Constitutive expression of the Id1 gene impairs mouse B cell development. Cell 79:893-900.[CrossRef][Medline]
43. Sun, X.-H., and D. Baltimore. 1991. An inhibitory domain of E12 prevents DNA binding in E12 homodimers but not in E12 heterodimers. Cell 64:459-470.[CrossRef][Medline]
44. Wiederkehr, T., B. Bukau, and A. Buchberger. 2002. Protein turnover: a CHIP programmed for proteolysis. Curr. Biol. 12:R26-R28.[CrossRef][Medline]
45. Xu, W., M. Marcu, X. Yuan, E. Mimnaugh, C. Patterson, and L. Neckers. 2002. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA 99:12847-12852.
46. Zhuang, Y., P. Cheng, and H. Weintraub. 1996. B-lymphocyte development is regulated by the combined dosage of three basic helix-loop-helix genes, E2A, E2-2, and HEB. Mol. Cell. Biol. 16:2898-2905.[Abstract]
47. Zhuang, Y., P. Soriano, and H. Weintraub. 1994. The helix-loop-helix gene E2A is required for B cell differentiation. Cell 79:875-884.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals< |
|---|